Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Urinary System Drugs > Finasteride for Sale > CAS 98319-26-799% Pharmaceutical Grade Finasteride for Hair Loss Treatment
CAS 98319-26-799% Pharmaceutical Grade Finasteride for Hair Loss Treatment buy - large image1
CAS 98319-26-799% Pharmaceutical Grade Finasteride for Hair Loss Treatment buy - image1

CAS 98319-26-799% Pharmaceutical Grade Finasteride for Hair Loss Treatment

GMP ISO 22 Inquiries

Unit Price: Get Latest Price
CAS No.:

98319-26-7

Grade:

Pharmaceutical Grade

Content:

99%

Brand:

XAZB

Packaging:

Foil Bag, Box, Drum

Price valid (until):

2022-12-31

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Herb Extracts,Cosmetic raw materails,API

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


    Product Description
    Product name Finasteride
    Cas 98319-26-7
    Brand XAZB
    Appearance White Powder
    Specification 99%
    Type Raw Materials
    Package 1Kg/25Kg/Drum or As per your request
    Storage Store in cool and dry places ,keep away from strong light
    Shelf life 2 years when properly stored

    Finasteride is an antiandrogen which acts by inhibiting type II 5-alpha reductase.It is used as a treatment inbenign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. Additionally, it is registered in many countries for androgenetic alopecia (male-pattern baldness).

    Finasteride was approved initially in 1992, a treatment for prostate enlargement, but the sponsor had studied 1 mg of finasteride and demonstrated hair growth in male pattern hair loss. On December 22, 1997, the FDA approved finasteride to treat male pattern hair loss.

    Function

    1) Used for treatment of hair loss;

    2) For the treatment of benign prostatic hyperplasia, enlarged prostate shrink, improve urinary flow and improvement of benign prostatic hyperplasia caused symptoms.

    Benign prostatic hyperplasia

    Physicians use finasteride for the treatment of BPH, informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about -8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.

    Male pattern baldness

    Finasteride is used to treat male pattern hair loss (androgenetic alopecia) in men only. Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken.

    Off-label uses

    Finasteride is sometimes used in hormone replacement therapy for male-to-female transsexuals in combination with a form of estrogen due to its antiandrogen properties. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited.

    Item Specification Test Results
    Characteristics White or off-white crystalline powder Complies
    Soluility Freely soluble in alcohol;practically insoluble in water Complies
    Identification IR-Spectrum
    HPLC
    Complies
    Specific Rotation -50°~-60° -58°
    Water ≤0.3% 0.1%
    Residue on Ignition ≤0.1% 0.01%
    Heavy Metals ≤10 <10
    Relative Material Major≤0.5
    Total≤1.0
    0.3
    0.5
    Residual Solvent Complies Complies
    Assay 98.5%~101.0% 99.2%
    Conclusion The result conforms the standard

    CAS 98319-26-799% Pharmaceutical Grade Finasteride for Hair Loss Treatment


    Certificates

    Basic Info
    Product Name:

    Finasteride

    Other Name:

    1H-Indeno[5,4-f]quinoline-7-carboxamide,N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-,(4aR,4bS,6aS,7S,9aS,9bS,11aR)-;4-Azaandrost-1-ene-17-carboxamide,N-(1,1-dimethylethyl)-3-oxo-,(5α,17β)-;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-Dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxamide;MK 906;Finasteride;Proscar;Prostide;Propecia;Finpecia;Finastid;Chibro-Proscar;Fincar;Fistide;Finax;Finast;Finara;Prosteride;N-(tert-Butyl)-3-oxo-4-aza-5α-androst-1-ene-17-carboxamide;Finalo;Geffina;Appecia;Finasterid Alternova

    CAS No.:

    98319-26-7

    Molecular Formula:

    C23H36N2O2

    InChIKeys:

    InChIKey=DBEPLOCGEIEOCV-WSBQPABSSA-N

    Molecular Weight:

    372.54

    Exact Mass:

    372.54

    EC Number:

    1308068-626-2

    UNII:

    57GNO57U7G

    NSC Number:

    741485

    DSSTox ID:

    DTXSID3020625

    NCI Thesaurus Code:

    C1099

    Color/Form:

    White to off-white crystalline solid

    ATC Code:

    G04CB01|D - Dermatologicals|G - Genito urinary system and sex hormones

    HScode:

    29379000

    Categories:

    Urinary System Drugs

    Characteristics
    PSA:

    58.2

    XLogP3:

    3

    Appearance:

    white to beige solid

    Density:

    1.065±0.06 g/cm3(Predicted)

    Melting Point:

    252-254 °C

    Boiling Point:

    576.6°C at 760 mmHg

    Flash Point:

    177.4ºC

    Refractive Index:

    1.524

    Water Solubility:

    H2O: insoluble ;DMSO: 32 mg/mL, soluble

    Storage Conditions:

    Store at RT

    Specific rotation:

    405 -59° (c = 1 in methanol)

    Collision Cross Section:

    200 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

    Experimental Properties:

    MP approx 257 °C (dried to anhydrous under nitrogen)

    Hazard Identification

    Classification of the substance or mixture

    Acute toxicity - Category 4, Oral

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H302 Harmful if swallowed

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    Response

    P301+P317 IF SWALLOWED: Get medical help.

    P330 Rinse mouth.

    Storage

    none

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Herb Extracts,Cosmetic raw materails,API

    Location:

    1403,Jinye B Block

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    8

    Total Annual Revenue:

    $2.5 million-$5 million

    Total Employees:

    11-50

    Year of Establishment:

    2015

    Xian ZB Biotech Co.,Ltd is a leading Manufactory supplier of Arbutin, Nicotinamide, Flucytosine based in Xi'an, Shaanxi, China. With a commitment to quality and customer satisfaction, Xian ZB Biotech Co.,Ltd has become a trusted name in the industry. Our product line includes a range of high-quality Arbutin, Nicotinamide, Flucytosine, which are available at competitive prices. Xian ZB Biotech Co.,Ltd has established itself as a reliable supplier of chemical products on the echemi.com.

  • Inquiry History
    22 Inquiries
    Country Product Purchase Quantity Date Posted
    Canada

    High quality Pure 99% Finasteride powder CAS 98319-26-7

    100 G Nov 16, 2023
    Lebanon

    Finasteride

    50 G Dec 5, 2025
    Italy

    Finasteride

    1000 MG Apr 18, 2025
    Pakistan

    Finasteride

    1 KG Nov 19, 2024
    Thailand

    Finasteride

    10 G Jul 8, 2024
    United States

    Finasteride

    10 G Mar 30, 2024
    Croatia

    Finasteride

    1 KG Sep 5, 2025
    Croatia

    Finasteride

    20 G Sep 3, 2025
    Italy

    Finasteride

    500 MG Apr 18, 2025
    New Zealand

    Finasteride powder

    10 G Sep 26, 2024
    Malaysia

    Finasteride

    100 G Aug 21, 2024
    United States

    Nitracaine (Crystal 99.9% min)

    2 G Jun 11, 2024
    Thailand

    High purity Finasteride

    100 G May 4, 2024
    United Kingdom

    Finasteride

    10 G Jan 10, 2024
    Germany

    Finasteride

    50 G Oct 23, 2024
    United States

    High purity Finasteride

    20 G Feb 27, 2026
    South Africa

    Finasteride

    100 G Feb 20, 2026
    Pakistan

    finasteride

    1 KG Oct 6, 2025
    Croatia

    Finasteride

    20 G Sep 12, 2025
    Canada

    Finasteride raw powder

    100 G Aug 18, 2025
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.